Phase II Trial of AZD0530 for Patients With Relapsed/Refractory Thymic Malignancies (Thymoma and Thymic Carcinoma).

Trial Profile

Phase II Trial of AZD0530 for Patients With Relapsed/Refractory Thymic Malignancies (Thymoma and Thymic Carcinoma).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2015

At a glance

  • Drugs Saracatinib (Primary)
  • Indications Malignant thymoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Jun 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
    • 26 Oct 2012 Planned End Date changed from 1 Jan 2012 to 1 Nov 2013 as reported by ClinicalTrials.gov.
    • 07 Jan 2011 Planned End Date changed from 1 Jan 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top